Pfizer Inc
NYSE:PFE
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
24.5384
31.39
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PFE stock under the Base Case scenario is 24.05 USD. Compared to the current market price of 25.65 USD, Pfizer Inc is Overvalued by 6%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Pfizer Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PFE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Pfizer Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Pfizer Inc. is a global leader in the pharmaceutical industry, renowned for its commitment to innovative research and development that drives breakthroughs in healthcare. Founded in 1849, Pfizer has evolved into a powerhouse, particularly highlighted by its pivotal role in developing one of the first COVID-19 vaccines in collaboration with BioNTech. This achievement not only underscored the company's rapid response capabilities but also significantly boosted its revenue, showcasing its ability to pivot in times of global health crises. Investors are drawn to Pfizer not just for its historical legacy, but also for its diverse portfolio that includes treatments across various therapeutic areas...
Pfizer Inc. is a global leader in the pharmaceutical industry, renowned for its commitment to innovative research and development that drives breakthroughs in healthcare. Founded in 1849, Pfizer has evolved into a powerhouse, particularly highlighted by its pivotal role in developing one of the first COVID-19 vaccines in collaboration with BioNTech. This achievement not only underscored the company's rapid response capabilities but also significantly boosted its revenue, showcasing its ability to pivot in times of global health crises. Investors are drawn to Pfizer not just for its historical legacy, but also for its diverse portfolio that includes treatments across various therapeutic areas such as oncology, immunology, and neurology, reflecting a balanced strategy poised for future growth.
As Pfizer continues to navigate a post-pandemic world, its focus on innovation remains a cornerstone of its business strategy. With a robust pipeline of drugs in late-stage development and a strong commitment to mergers and acquisitions, Pfizer is determined to maintain market leadership while expanding its therapeutic offerings. Importantly, the company is also committed to shareholder value, consistently returning profits through dividends and share buybacks. For investors, Pfizer represents a compelling opportunity, merging stability with the potential for growth in an ever-evolving healthcare landscape, driven by advancements in science and technology.
Pfizer Inc. operates through several core business segments, each focusing on different areas of healthcare and pharmaceuticals. Here are the primary segments:
-
Innovative Health: This segment includes prescription medicines across various therapeutic areas, such as oncology, immunology, cardiology, internal medicine, and vaccines. The focus is on developing and delivering novel therapies and vaccines that address unmet medical needs.
-
Essential Health: This segment encompasses a wide range of established products, including off-patent branded medications, generic drugs, and biosimilars. The goal here is to provide essential medications for patients, often at lower costs, while maintaining a strong portfolio in areas like anti-infectives, sterile injectables, and established cardiovascular products.
-
Vaccines: This part of the business focuses specifically on the research, development, and commercialization of vaccines. Pfizer has gained significant attention for its COVID-19 vaccine, developed in partnership with BioNTech, which has significantly boosted its visibility and financial performance.
-
Consumer Healthcare: Although this segment has been spun off into a joint venture named Haleon, it previously included over-the-counter products for consumer health needs.
-
Global Established Pharma (GEP): This segment targets markets outside the U.S. and focuses on providing established medications and innovative products to patients globally.
-
Research & Development (R&D): While not a standalone segment, R&D plays a crucial role across all segments, focusing on discovering new treatments and improving existing therapies, particularly in high-impact therapeutic areas.
Understanding these core segments provides insight into Pfizer's strategic approach to ensuring broad coverage in the pharmaceuticals and healthcare landscape while maintaining a focus on innovation and addressing global health challenges.
Pfizer Inc. possesses several unique competitive advantages that distinguish it from its rivals in the pharmaceutical industry:
-
Strong R&D Capabilities: Pfizer has a robust research and development pipeline, backed by significant investment in innovation. This allows the company to develop new therapies and maintain a competitive edge through cutting-edge drugs.
-
Diverse Product Portfolio: With a wide range of products, including blockbuster medications, vaccines (notably its COVID-19 vaccine), and treatments across various therapeutic areas, Pfizer can leverage its portfolio to mitigate risks associated with patent expirations and market fluctuations.
-
Global Presence: Pfizer's extensive global distribution network enables it to access diverse markets, enhancing its ability to scale operations and reach a wider customer base. This global footprint also aids in quicker response to emerging health needs.
-
Strong Brand Recognition: Pfizer has built a reputable brand over decades, associated with quality and innovation. This strong brand equity fosters trust with healthcare professionals and patients, facilitating product adoption.
-
Strategic Alliances and Partnerships: Collaborations with biotech firms, academic institutions, and other organizations, such as the partnership with BioNTech for the COVID-19 vaccine, amplify Pfizer's capabilities in research, development, and distribution.
-
Established Regulatory Expertise: Pfizer has extensive knowledge and experience navigating complex regulatory environments across different countries, which can expedite the approval process for new drugs and vaccines compared to competitors with less experience.
-
Financial Strength: Pfizer’s significant revenues and cash flow allow for substantial reinvestment in R&D, marketing, and acquisitions. This financial resilience also enables the company to withstand competitive pressures.
-
Innovative Drug Delivery Systems: Pfizer actively invests in drug delivery technologies, enhancing the efficacy and convenience of its medications, thus improving patient adherence and treatment outcomes.
-
Supply Chain Robustness: Pfizer has developed a resilient supply chain that can adapt to disruptions, ensuring consistent delivery of products even during crises, as evidenced during the COVID-19 pandemic.
-
Focus on Sustainability: Recent initiatives toward sustainability and corporate social responsibility (CSR) resonate well with a growing base of socially-conscious investors and consumers, enhancing brand loyalty and market positioning.
These advantages collectively position Pfizer to compete effectively in the fast-evolving pharmaceutical landscape, drive growth, and sustain long-term profitability.
Pfizer Inc., as a leading global pharmaceutical company, faces several risks and challenges moving forward. Some of the most significant include:
-
Patent Expiration: Many of Pfizer’s revenue-generating drugs are approaching patent expiration, which poses a risk of increased competition from generic medications. This can lead to a significant loss in market share and revenue.
-
Regulatory Environment: Pfizer operates in a heavily regulated industry. Changes in regulations, especially regarding drug approvals, pricing, and healthcare policies, could impact Pfizer’s ability to bring new products to market or maintain profitability.
-
Market Competition: The pharmaceutical sector is highly competitive. The emergence of biosimilars and generic drug manufacturers can threaten Pfizer’s market position, particularly for its key products.
-
R&D Challenges: Pfizer invests heavily in research and development (R&D). The pharmaceutical industry has a high failure rate for drug development. There is always a risk that pipeline products may not receive approval or may fail in clinical trials.
-
Public Perception and Trust: The ongoing debates around drug pricing and pharmaceutical ethics can affect public perception. Any negative media coverage can impact consumer trust and brand reputation.
-
Supply Chain Disruptions: Global events, such as pandemics or geopolitical tensions, can disrupt supply chains, hindering the production and distribution of Pfizer's products.
-
Changing Healthcare Landscape: Shifts in healthcare management, such as the movement towards value-based care and changes in insurance coverage, may affect drug pricing and patient access to medications.
-
Economic Conditions: Broader economic challenges, such as recessions or inflation, can influence healthcare spending and potentially reduce demand for certain medications.
-
Innovative Disruption: As technology advances, new treatment modalities (like gene therapy, personalized medicine, and digital health solutions) could disrupt traditional pharmaceutical business models.
-
Litigation Risks: Pfizer is subject to various litigations, including patent disputes and product liability claims, which could have financial implications.
To mitigate these risks, Pfizer will need to continue innovating, managing its product pipeline effectively, engaging with regulatory bodies, and maintaining ethical practices in its business operations.
Revenue & Expenses Breakdown
Pfizer Inc
Balance Sheet Decomposition
Pfizer Inc
Current Assets | 37.8B |
Cash & Short-Term Investments | 7.1B |
Receivables | 15.1B |
Other Current Assets | 15.6B |
Non-Current Assets | 178.4B |
Long-Term Investments | 11.1B |
PP&E | 19B |
Intangibles | 129.7B |
Other Non-Current Assets | 18.6B |
Current Liabilities | 43.8B |
Accounts Payable | 5.1B |
Accrued Liabilities | 2.6B |
Short-Term Debt | 8.2B |
Other Current Liabilities | 27.9B |
Non-Current Liabilities | 84.7B |
Long-Term Debt | 57.5B |
Other Non-Current Liabilities | 27.2B |
Earnings Waterfall
Pfizer Inc
Revenue
|
60.1B
USD
|
Cost of Revenue
|
-17.5B
USD
|
Gross Profit
|
42.6B
USD
|
Operating Expenses
|
-29.4B
USD
|
Operating Income
|
13.1B
USD
|
Other Expenses
|
-8.9B
USD
|
Net Income
|
4.3B
USD
|
Free Cash Flow Analysis
Pfizer Inc
USD | |
Free Cash Flow | USD |
Pfizer reported a robust Q3 2024 with revenues of $17.7 billion, reflecting a 32% operational growth. They raised their full-year revenue guidance by $1.5 billion, now expecting $61 to $64 billion, and adjusted earnings per share to $2.75 to $2.95. Noteworthy contributions were from PAXLOVID and COMIRNATY, estimated at $5.5 billion and $5 billion, respectively. The non-COVID business grew 14% year-over-year, supporting a stable operational foundation. Pfizer is on track to deliver $4 billion in cost savings while maintaining a commitment to growing dividends, demonstrating strong cash flow management as they continue integrating recent acquisitions.
What is Earnings Call?
PFE Profitability Score
Profitability Due Diligence
Pfizer Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Pfizer Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
PFE Solvency Score
Solvency Due Diligence
Pfizer Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Pfizer Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PFE Price Targets Summary
Pfizer Inc
According to Wall Street analysts, the average 1-year price target for PFE is 32.95 USD with a low forecast of 25.25 USD and a high forecast of 47.25 USD.
Dividends
Current shareholder yield for PFE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
PFE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Pfizer Inc. is a research-based global biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 79,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The firm offers therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator in development for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. The firm works across markets to develop wellness, prevention, treatments and cures. The company collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. The firm's medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness.
Contact
IPO
Employees
Officers
The intrinsic value of one PFE stock under the Base Case scenario is 24.05 USD.
Compared to the current market price of 25.65 USD, Pfizer Inc is Overvalued by 6%.